DC Business DC

Novavax earns key FDA status for its flu vaccine. Wall Street took it well.

Washington Business Journal

Jan 15, 2020

Novavax Inc. just got a critical regulatory assist for its experimental seasonal flu vaccine, news that boosted its stock price and gave a glimmer of hope for its first potential p…

Read the full story at Washington Business Journal

Novavax earns key FDA status for its flu vaccine. Wall Street took it well.

More from DC Business

Shilling Canning files for bankruptcy protection amid rent struggles

Steve Case's Revolution teams with Hilton to deliver luxury Costa Rican resort 19 years in the making

Challenge to ACA preventive-care panel draws skepticism from Supreme Court

Can Trump remove Powell as Fed chair before his term ends?

Amazon closing one of its Northern Virginia supermarkets

International travelers give D.C.'s hospitality business only slight boost

Drone firm announces Virginia expansion and college partnership

Mixed-use development in downtown Bethesda looks to add more retail, residences